drugset / Trial / NCT00515944

Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products

NCT00515944

Phase 1 Completed 30 enrolled Merz Pharmaceuticals GmbH
RandomizedSingle-groupDouble-blind

Summary

Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening. Botulinum toxin type A is used for certain neurological and aesthetic treatments. This study will investigate the migration potential of Xeomin®.

Timeline

Start
2007-08
Primary completion
2008-02
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic Intramuscular

Indications

No indication recorded.